CANCER DIAGNOSTICS MARKET The global cancer burden encompassed 50.6 million people living with cancer, 19.3 million new cases and 10.0 million deaths in 2020.1 The incidence of cancer is expected to reach 28.4 million new cases by 2040 due to population aging and growth. Cancer is a leading cause of premature death with the highest burdens in China, Europe and North America. The cancer burden can be reduced by improved prevention, early detection, cancer screening programs and effective treatment to improve patient outcomes and reduce mortality. Cancer is often detected at late-stage (stages III and IV) after symptoms have appeared, resulting in a poor prognosis. Many existing diagnostic tests have high false-positives and/or insufficient sensitivity for earlystage cancer (stages I and II) and screening programs have poor participation rates due to the test invasiveness, inconvenience, inaccessibility and cost. Earlier, more accurate and cost-effective diagnostics could improve treatment options, patient outcomes and survival.2 INOVIQ is developing non-invasive, diagnostics using its proprietary SubB2M (improves existing cancer biomarker tests) and exosome (liquid biopsies and companion diagnostics) technologies for screening, diagnosis, treatment selection and monitoring of cancer and other diseases. INOVIQ’s diagnostics pipeline currently includes blood tests for detection and monitoring of breast and ovarian cancers. Breast cancer is the most common cancer with 2.3 million cases and 685 million deaths worldwide1, and a global diagnostics market valued at US$4.3 billion in 2022.3 Ovarian cancer is the world’s deadliest gynaecological cancer with 314,000 cases and 207,000 deaths worldwide1, and a global diagnostic market expected to reach over US$1.8 billion by 2026.4 EXOSOMES MARKET FOR RESEARCH, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS Exosomes (or small extracellular vesicles, sEVs) are released by all cells and perform key roles in intercellular communication, immune regulation and disease progression. They carry molecular cargo including DNA, RNAs, proteins and lipids that act as cell messengers or biomarkers of disease. Exosomes have enormous potential in applications for research, diagnosis and treatment of cancer, neurodegenerative, cardiovascular, infectious and other diseases. The global exosomes market for research, diagnostics and therapeutics was valued at US$325.8 million in 2023 and is forecast to reach US$2.6 billion by 2030, growing at a CAGR of 29.9%.5 It is predicted the market will be $6.8B by 2032 as more diagnostics and therapeutics are commercialised.6 Market growth is driven by increased investment in exosome research, the rising prevalence of chronic diseases, and adoption of liquid biopsies and precision medicine. The key challenge remains inadequate exosome isolation and production methods. INOVIQ is harnessing the power of exosomes for biomarker discovery, diagnostic and therapeutic applications. The Company has commercialised its EXONET exosome isolation technology with global distribution partner Promega, is advancing diagnostic tests for early detection of ovarian cancer, and progressing early-stage exosome therapeutics for solid tumours. 1 Sung H et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660 2 SEER18 2010-2016 3 2023. Breast Cancer Diagnostics Market, 2023-2030: https://www.grandviewresearch.com/industry-analysis/ breast-cancer-diagnostics-market 4 2019. Ovarian Cancer Diagnostics Market. https://www. globenewswire.com/news-release/2019/08/07/1898453/0/ en/Ovarian-Cancer-Diagnostics-Market-Size-Worth-US-1-8Bn-by-2026.html 5 2024. Exosomes Market: Global Industry Analysis and Forecast for the Period 2024-2030. MMR: https://www. maximizemarketresearch.com/market-report/exosomesmarket/189733/ 6 2023. Exosome Diagnostics and Therapeutics Market to 2032. MarketsandMarkets: https://www.marketsandmarkets. com/Market-Reports/exosome-diagnostics-therapeuticsmarket-198025144.html Click to edit Master title style 4 Lipid bilayer DNA RNA Surface proteins Protein Extracellular Vesicle (EV) 7 Annual Report 2024 Review of Operations
RkJQdWJsaXNoZXIy MjE2NDg3